GLP1R and type 2 diabetes mellitus: Several large cardiovascular outcome trials (CVOTs) have demonstrated that glucose-lowering agents belonging to the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class significantly reduce cardiovascular events vs baseline glucose-lowering therapy in high-risk individuals with T2D [1, 5, 6].